Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LBPHNYSE:QGENNASDAQ:ROIVNASDAQ:RVMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLBPHLongboard Pharmaceuticals$59.98$59.88$15.64▼$60.03$2.34B11.16 million shsN/AQGENQiagen$44.36+1.2%$41.49$37.63▼$49.30$9.86B0.671.16 million shs1.42 million shsROIVRoivant Sciences$10.62-1.3%$10.52$8.73▼$13.06$7.58B1.235.58 million shs6.31 million shsRVMDRevolution Medicines$37.73+2.1%$37.53$29.17▼$62.40$7.03B1.111.51 million shs2.27 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLBPHLongboard Pharmaceuticals0.00%0.00%0.00%0.00%+221.44%QGENQiagen+1.19%+5.01%+4.40%+15.60%+6.06%ROIVRoivant Sciences-1.30%-2.66%-5.09%+2.31%-1.94%RVMDRevolution Medicines+2.06%-2.61%-9.02%-3.45%-0.45%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationLBPHLongboard PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AQGENQiagen3.2157 of 5 stars1.22.01.74.52.81.71.3ROIVRoivant Sciences2.3165 of 5 stars3.53.00.00.02.22.50.0RVMDRevolution Medicines4.2677 of 5 stars4.50.00.04.73.62.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLBPHLongboard Pharmaceuticals 2.38Hold$63.005.04% UpsideQGENQiagen 2.30Hold$48.429.14% UpsideROIVRoivant Sciences 3.00Buy$17.5064.78% UpsideRVMDRevolution Medicines 3.00Buy$67.0877.80% UpsideCurrent Analyst Ratings BreakdownLatest LBPH, QGEN, ROIV, and RVMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025ROIVRoivant SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.005/14/2025RVMDRevolution MedicinesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$73.00 ➝ $72.005/8/2025RVMDRevolution MedicinesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$67.005/8/2025RVMDRevolution MedicinesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$70.00 ➝ $75.005/8/2025RVMDRevolution MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$87.00 ➝ $80.005/8/2025RVMDRevolution MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$57.00 ➝ $57.004/28/2025RVMDRevolution MedicinesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$67.00 ➝ $67.004/21/2025QGENQiagenRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$42.00 ➝ $43.004/21/2025ROIVRoivant SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.004/8/2025RVMDRevolution MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$59.00 ➝ $59.004/4/2025QGENQiagenRedburn AtlanticSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLBPHLongboard PharmaceuticalsN/AN/AN/AN/A$1.67 per shareN/AQGENQiagen$2.00B4.92$3.69 per share12.01$16.08 per share2.76ROIVRoivant Sciences$122.59M61.82N/AN/A$7.76 per share1.37RVMDRevolution Medicines$742K9,471.55N/AN/A$11.09 per share3.40Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLBPHLongboard Pharmaceuticals-$54.42M-$2.23N/AN/AN/AN/A-33.03%-30.90%N/AQGENQiagen$83.59M$0.40123.5218.032.394.23%13.92%8.40%7/30/2025 (Estimated)ROIVRoivant Sciences$4.35B-$0.15N/AN/AN/A-119.54%-14.05%-12.81%5/29/2025 (Estimated)RVMDRevolution Medicines-$436.37M-$4.00N/AN/AN/AN/A-33.67%-30.08%8/6/2025 (Estimated)Latest LBPH, QGEN, ROIV, and RVMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/29/2025Q4 2025ROIVRoivant Sciences-$0.16N/AN/AN/A$62.17 millionN/A5/7/2025Q1 2025QGENQiagen$0.50$0.55+$0.05$0.41$465.66 million$483.46 million5/7/2025Q1 2025RVMDRevolution Medicines-$1.12-$1.13-$0.01-$1.13N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLBPHLongboard PharmaceuticalsN/AN/AN/AN/AN/AQGENQiagen$0.250.56%N/A62.50%N/AROIVRoivant SciencesN/AN/AN/AN/AN/ARVMDRevolution MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLBPHLongboard PharmaceuticalsN/A15.9715.97QGENQiagen0.383.613.09ROIVRoivant SciencesN/A37.9137.91RVMDRevolution MedicinesN/A14.2414.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLBPHLongboard Pharmaceuticals63.28%QGENQiagen70.00%ROIVRoivant Sciences64.76%RVMDRevolution Medicines94.34%Insider OwnershipCompanyInsider OwnershipLBPHLongboard Pharmaceuticals4.64%QGENQiagen9.00%ROIVRoivant Sciences7.90%RVMDRevolution Medicines8.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLBPHLongboard Pharmaceuticals2039.05 million37.23 millionOptionableQGENQiagen6,030222.29 million201.89 millionOptionableROIVRoivant Sciences860713.55 million657.18 millionOptionableRVMDRevolution Medicines250186.27 million154.76 millionOptionableLBPH, QGEN, ROIV, and RVMD HeadlinesRecent News About These CompaniesRevolution Medicines (NASDAQ:RVMD) Trading Down 4% - Here's WhyMay 28 at 1:06 PM | marketbeat.comPolar Asset Management Partners Inc. Boosts Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)May 28 at 5:36 AM | marketbeat.comRevolution Medicines’ SWOT analysis: stock shows promise amid clinical progressMay 27 at 8:58 PM | investing.comNuveen Asset Management LLC Raises Stock Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)May 26 at 3:51 AM | marketbeat.comD. E. Shaw & Co. Inc. Decreases Stock Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)May 26 at 3:34 AM | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) Shares Purchased by ProShare Advisors LLCMay 23, 2025 | marketbeat.comBank of America Corp DE Has $17.54 Million Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)May 23, 2025 | marketbeat.comWoodline Partners LP Has $169.96 Million Stock Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)May 22, 2025 | marketbeat.comSoleus Capital Management L.P. Sells 503,500 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)May 21, 2025 | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) Shares Purchased by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.May 21, 2025 | marketbeat.comRevolution Medicines Inc.May 20, 2025 | wsj.comTang Capital Management LLC Invests $4.37 Million in Revolution Medicines, Inc. (NASDAQ:RVMD)May 20, 2025 | marketbeat.comTema Etfs LLC Invests $1.99 Million in Revolution Medicines, Inc. (NASDAQ:RVMD)May 20, 2025 | marketbeat.comMan Group plc Buys 65,567 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)May 20, 2025 | marketbeat.comDeutsche Bank AG Has $7.76 Million Stock Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)May 20, 2025 | marketbeat.comPolar Asset Management Partners Inc. Buys 10,900 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)May 19, 2025 | marketbeat.comPolar Capital Holdings Plc Invests $32.83 Million in Revolution Medicines, Inc. (NASDAQ:RVMD)May 18, 2025 | marketbeat.comJefferies Financial Group Inc. Buys New Stake in Revolution Medicines, Inc. (NASDAQ:RVMD)May 18, 2025 | marketbeat.comMPM Bioimpact LLC Boosts Stake in Revolution Medicines, Inc. (NASDAQ:RVMD)May 16, 2025 | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) is Paradigm Biocapital Advisors LP's 4th Largest PositionMay 16, 2025 | marketbeat.comNextech Invest Ltd. Buys 1,304,347 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)May 16, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLBPH, QGEN, ROIV, and RVMD Company DescriptionsLongboard Pharmaceuticals NASDAQ:LBPHLongboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.Qiagen NYSE:QGEN$44.36 +0.51 (+1.16%) Closing price 05/28/2025 03:59 PM EasternExtended Trading$44.38 +0.02 (+0.03%) As of 05/28/2025 04:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.Roivant Sciences NASDAQ:ROIV$10.62 -0.14 (-1.30%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$10.69 +0.07 (+0.66%) As of 05/28/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.Revolution Medicines NASDAQ:RVMD$37.73 +0.76 (+2.06%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$37.40 -0.33 (-0.89%) As of 05/28/2025 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
